KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Core Insights - Merck announced positive topline results from the Phase 3 KEYNOTE-B15 trial for patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy [1] - The trial evaluated the combination of KEYTRUDA® (pembrolizumab) and Padcev® (enfortumab vedotin-ejfv) as neoadjuvant and adjuvant treatment, showing statistically significant results [1] Company Summary - Merck, known as MSD outside the United States and Canada, is focusing on innovative cancer treatments [1] - The positive results from the KEYNOTE-B15 trial may enhance Merck's position in the oncology market [1] Industry Summary - The trial results contribute to the growing body of evidence supporting immunotherapy and targeted therapy combinations in treating bladder cancer [1] - The findings may influence treatment protocols and patient outcomes in the field of oncology [1]